Page last updated: 2024-10-30

edaravone and Infarction, Middle Cerebral Artery

edaravone has been researched along with Infarction, Middle Cerebral Artery in 42 studies

Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.

Research Excerpts

ExcerptRelevanceReference
"DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment."8.31A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023)
"Edaravone dexborneol (EDB) is a traditional prescription that consists of two components, edaravone and (+)-borneol, which have synergistic antioxidant and anti-inflammatory activities in animal models of ischemic stroke."8.12Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke. ( Ding, L; Hu, R; Liang, J; Liu, X; Song, B; Xu, Y; Zhang, W, 2022)
"Our previous studies confirm that exogenous reduced nicotinamide adenine dinucleotide phosphate (NADPH) exerts a neuroprotective effect in animal models of ischemic stroke, and its primary mechanism is related to anti-oxidative stress and improved energy metabolism."8.12NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke. ( Chen, Z; Han, R; Li, M; Mao, GH; Qin, ZH; She, J; Sheng, R; Wang, F; Wang, XX; Wu, JC; Zhang, R, 2022)
"Edaravone attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia."7.80Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. ( Johshita, H; Miyazaki, H; Okamura, K; Shiokawa, Y; Tsubokawa, T, 2014)
"Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction."7.78Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012)
" Here, we developed macrophage-derived exosomes (Exo) containing Edv (Exo + Edv) to improve the bioavailability of Edv and enhance the neuroprotective effects in a rat model of permanent middle cerebral artery occlusion (PMCAO)."5.56Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020)
"Diabetic rats exposed to 2-hr middle cerebral artery occlusion (MCAO) and 22 hr of reperfusion significantly had increased infarct, oedema volume and functional neurological deficits as compared to sham-operated rats."5.38Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012)
"Permanent focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO)."5.33Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005)
"DL-3-n-butylphthalide (NBP) and edaravone dexborneol (Eda-Dex) are two promising reagents for stroke treatment."4.31A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats. ( Cai, C; Cui, Y; Deng, L; He, B; Wang, L; Wang, X; Yang, Y; Zhang, H; Zhou, W; Zhu, B, 2023)
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."4.21 ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022)
"Edaravone has been widely used in the treatment of acute ischemic stroke."4.12Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats. ( Luo, HY; Parikh, A; Xiong, YX; Ye, QY; Zhao, LQ; Zhou, XF, 2022)
"Edaravone dexborneol (EDB) is a traditional prescription that consists of two components, edaravone and (+)-borneol, which have synergistic antioxidant and anti-inflammatory activities in animal models of ischemic stroke."4.12Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke. ( Ding, L; Hu, R; Liang, J; Liu, X; Song, B; Xu, Y; Zhang, W, 2022)
"Our previous studies confirm that exogenous reduced nicotinamide adenine dinucleotide phosphate (NADPH) exerts a neuroprotective effect in animal models of ischemic stroke, and its primary mechanism is related to anti-oxidative stress and improved energy metabolism."4.12NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke. ( Chen, Z; Han, R; Li, M; Mao, GH; Qin, ZH; She, J; Sheng, R; Wang, F; Wang, XX; Wu, JC; Zhang, R, 2022)
"DL‑3‑n‑butylphthalide (NBP) and 3‑methyl‑1- phenyl‑2‑pyrazolin‑5‑one (edaravone) are acknowledged neuroprotective agents that protect against ischemic stroke."4.02Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke. ( Cheng, Y; Guan, Y; Guo, L; Li, P; Liu, Y; Wu, Q, 2021)
"Edaravone attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia."3.80Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. ( Johshita, H; Miyazaki, H; Okamura, K; Shiokawa, Y; Tsubokawa, T, 2014)
"Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction."3.78Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012)
"We demonstrate that edaravone inhibits rtPA-induced cerebral hemorrhage in the ischemic brain of rats via the inhibition of MMP-9 expression in vivo, which is substantiated by inhibition of MMP-9 expression and NF-kappaB activation in HBECs."3.75Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. ( Kinouchi, T; Kitazato, KT; Nagahiro, S; Shimada, K; Tada, Y; Uno, M; Yagi, K, 2009)
"The effects of ozagrel (CAS 82571-53-7), a thromboxane A2-synthetase inhibitor, and norphenazone (CAS 89-25-8), a free-radical scavenger, on cerebral infarction were assessed using the suture-induced middle cerebral artery occlusion (MCAO) model and a microthrombosis model."3.72Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger. ( Ichikawa, K; Imamura, T; Kiguchi, S; Kobayashi, K; Kojima, M; Yamazaki, Y, 2003)
" Here, we developed macrophage-derived exosomes (Exo) containing Edv (Exo + Edv) to improve the bioavailability of Edv and enhance the neuroprotective effects in a rat model of permanent middle cerebral artery occlusion (PMCAO)."1.56Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke. ( Li, F; Liang, J; Shi, Y; Zhao, L, 2020)
"Rat transient middle cerebral artery occlusion (MCAO) model was established."1.43Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016)
"SD rats were subjected to 2-h-middle cerebral artery occlusion (MCAO)."1.42The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. ( Hua, K; Huang, ZJ; Ji, H; Li, TT; Sheng, X; Wang, LN; Zhang, YH, 2015)
"Results from transient middle cerebral artery occlusion and permanent middle cerebral artery occlusion model, indicated that 3d could significantly reduce infarct size, improve neurobehavioral deficits, and prominently decrease attenuation of cerebral damage."1.42Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent. ( Lan, Z; Lei, M; Li, J; Liang, Z; Xu, W; Xu, X; Zhang, X; Zhao, C, 2015)
"In response to cerebral ischemia, activated microglia release excessive inflammatory mediators which contribute to neuronal damage."1.40Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. ( Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014)
"Diabetic rats exposed to 2-hr middle cerebral artery occlusion (MCAO) and 22 hr of reperfusion significantly had increased infarct, oedema volume and functional neurological deficits as compared to sham-operated rats."1.38Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012)
"In vivo, rat transient middle cerebral artery occlusion (MCAO) model was established."1.38Protective effects of MCI-186 on transplantation of bone marrow stromal cells in rat ischemic stroke model. ( Ding, XS; Gu, XS; Han, Q; Huang, H; Huang, HF; Liu, XF; Shen, LH; Wu, EB; Ye, M; Zhang, C, 2012)
"Oral montelukast (0."1.37Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats. ( Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R, 2011)
"To validate this new model of reperfusion injury, we used two well characterized neuroprotectants, estrogen and edaravone."1.36A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery. ( Connell, BJ; Saleh, TM, 2010)
"Mice subjected to 2-h filamental middle cerebral artery occlusion were treated with NBO (95% O2, during the ischemia) alone, with edaravone (1."1.35Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice. ( Hara, H; Iwama, T; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2008)
"Edaravone treatment significantly reduced the lesion volume and improved the neurological score."1.35Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model. ( Fujii, M; Fujisawa, H; Gondo, T; Izuma, H; Kajiwara, K; Kato, S; Nomura, S; Oka, F; Suzuki, M; Uozumi, K, 2009)
"Treatment with serofendic acid (1-30 nmol) reduced the infarct volume in a dose-dependent manner."1.35Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats. ( Akaike, A; Katsuki, H; Kume, T; Nakamura, T; Niidome, T; Sugimoto, H, 2008)
"Permanent focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO)."1.33Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (30.95)29.6817
2010's17 (40.48)24.3611
2020's12 (28.57)2.80

Authors

AuthorsStudies
Zhang, H4
Yu, P1
Lin, H1
Jin, Z1
Zhao, S2
Zhang, Y5
Xu, Q1
Jin, H1
Liu, Z1
Yang, W2
Zhang, L1
Guan, Y1
Li, P2
Liu, Y4
Guo, L1
Wu, Q1
Cheng, Y1
Zhao, LQ1
Parikh, A1
Xiong, YX1
Ye, QY1
Zhou, XF1
Luo, HY1
Huang, Y2
Zhang, X4
Zhang, C2
Xu, W2
Li, W2
Feng, Z2
Zhao, K1
Liu, W4
Wang, L5
Liu, C4
Dai, Z1
Li, T2
Tang, B1
Hu, R1
Liang, J2
Ding, L1
Zhang, W1
Liu, X2
Song, B1
Xu, Y2
Zhu, B1
Yang, Y4
Cai, C2
Wang, X3
Deng, L2
He, B1
Cui, Y1
Zhou, W2
Wu, XL1
Lu, SS1
Liu, MR1
Tang, WD1
Chen, JZ1
Zheng, YR1
Ahsan, A1
Cao, M1
Jiang, L2
Hu, WW1
Wu, JY1
Chen, Z3
Zhang, XN1
Li, F1
Zhao, L1
Shi, Y1
Nese, M1
Riboli, G1
Brighetti, G1
Sassi, V1
Camela, E1
Caselli, G1
Sassaroli, S1
Borlimi, R1
Aucoin, M1
Cooley, K1
Saunders, PR1
Carè, J1
Anheyer, D1
Medina, DN1
Cardozo, V1
Remy, D1
Hannan, N1
Garber, A1
Velayos, M1
Muñoz-Serrano, AJ1
Estefanía-Fernández, K1
Sarmiento Caldas, MC1
Moratilla Lapeña, L1
López-Santamaría, M1
López-Gutiérrez, JC1
Li, J2
Zhang, J1
Shen, S1
Zhang, B2
Yu, WW1
Toyoda, H1
Huang, DQ1
Le, MH1
Nguyen, MH1
Huang, R1
Zhu, L1
Wang, J6
Xue, L1
Liu, L2
Yan, X2
Huang, S1
Li, Y6
Xu, T1
Li, C2
Ji, F1
Ming, F1
Zhao, Y2
Cheng, J1
Wang, Y3
Zhao, H1
Hong, S1
Chen, K2
Zhao, XA1
Zou, L1
Sang, D1
Shao, H1
Guan, X1
Chen, X3
Chen, Y4
Wei, J1
Zhu, C1
Wu, C2
Moore, HB1
Barrett, CD1
Moore, EE1
Jhunjhunwala, R1
McIntyre, RC1
Moore, PK1
Hajizadeh, N1
Talmor, DS1
Sauaia, A1
Yaffe, MB1
Lin, Y1
Dong, Y1
Wu, Y1
Bao, Y1
Yan, H2
Ma, J1
Fernández-Cuadros, ME1
Albaladejo-Florín, MJ1
Álava-Rabasa, S1
Usandizaga-Elio, I1
Martinez-Quintanilla Jimenez, D1
Peña-Lora, D1
Neira-Borrajo, I1
López-Muñoz, MJ1
Rodríguez-de-Cía, J1
Pérez-Moro, OS1
Abdallah, M1
Alsaleh, H1
Baradwan, A1
Alfawares, R1
Alobaid, A1
Rasheed, A1
Soliman, I1
Wendel Garcia, PD1
Fumeaux, T1
Guerci, P1
Heuberger, DM1
Montomoli, J2
Roche-Campo, F1
Schuepbach, RA1
Hilty, MP1
Poloni, TE1
Carlos, AF1
Cairati, M1
Cutaia, C1
Medici, V1
Marelli, E1
Ferrari, D1
Galli, A1
Bognetti, P1
Davin, A1
Cirrincione, A1
Ceretti, A1
Cereda, C1
Ceroni, M1
Tronconi, L1
Vitali, S1
Guaita, A1
Leeds, JS1
Raviprakash, V1
Jacques, T1
Scanlon, N1
Cundall, J1
Leeds, CM1
Riva, A1
Gray, EH1
Azarian, S1
Zamalloa, A1
McPhail, MJW1
Vincent, RP1
Williams, R1
Chokshi, S1
Patel, VC1
Edwards, LA1
Alqarawi, W1
Birnie, DH1
Golian, M1
Nair, GM1
Nery, PB1
Klein, A1
Davis, DR1
Sadek, MM1
Neilipovitz, D1
Johnson, CB1
Green, MS1
Redpath, C1
Miller, DC1
Beamer, P1
Billheimer, D1
Subbian, V1
Sorooshian, A1
Campbell, BS1
Mosier, JM1
Novaretti, JV1
Astur, DC1
Cavalcante, ELB1
Kaleka, CC1
Amaro, JT1
Cohen, M1
Huang, W1
Ling, Y1
Qian, ZP1
Zhang, YY1
Huang, D1
Xu, SB1
Liu, XH1
Xia, L1
Lu, SH1
Lu, HZ1
Zhang, R3
Ma, JX1
Tang, S1
Li, CM1
Wan, J1
Wang, JF1
Ma, JQ1
Luo, JJ1
Chen, HY2
Mi, SL1
Chen, SY1
Su, YG1
Ge, JB1
Milheiro, SA1
Gonçalves, J1
Lopes, RMRM1
Madureira, M1
Lobo, L1
Lopes, A1
Nogueira, F1
Fontinha, D1
Prudêncio, M1
M Piedade, MF1
Pinto, SN1
Florindo, PR1
Moreira, R1
Castillo-Lora, J1
Delley, MF1
Laga, SM1
Mayer, JM1
Sutjarit, N1
Thongon, N1
Weerachayaphorn, J1
Piyachaturawat, P1
Suksamrarn, A1
Suksen, K1
Papachristou, DJ1
Blair, HC1
Hu, Y1
Shen, P1
Zeng, N1
Yan, D1
Cui, L1
Yang, K2
Zhai, C1
Yang, M1
Lao, X1
Sun, J1
Ma, N1
Wang, S1
Ye, W1
Guo, P1
Rahimi, S1
Singh, MP1
Gupta, J1
Nakanishi, I1
Ohkubo, K1
Shoji, Y1
Fujitaka, Y1
Shimoda, K1
Matsumoto, KI1
Fukuhara, K1
Hamada, H1
van der Boom, T1
Gruppen, EG1
Lefrandt, JD1
Connelly, MA1
Links, TP1
Dullaart, RPF1
Berry, JD1
Bedlack, R1
Mathews, D1
Agnese, W1
Apple, S1
Meloncelli, S1
Divizia, M1
Germani, G1
Adefegha, SA1
Bottari, NB1
Leal, DB1
de Andrade, CM1
Schetinger, MR1
Martínez-Velasco, A1
Perez-Ortiz, AC1
Antonio-Aguirre, B1
Martínez-Villaseñor, L1
Lira-Romero, E1
Palacio-Pastrana, C1
Zenteno, JC1
Ramirez, I1
Zepeda-Palacio, C1
Mendoza-Velásquez, C1
Camacho-Ordóñez, A1
Ortiz Bibriesca, DM1
Estrada-Mena, FJ1
Martin, BL1
Thompson, LC1
Kim, YH2
Snow, SJ1
Schladweiler, MC1
Phillips, P1
Harmon, M1
King, C1
Richards, J1
George, I1
Haykal-Coates, N1
Gilmour, MI1
Kodavanti, UP1
Hazari, MS1
Farraj, AK1
Shen, Z1
Zou, Y1
Gao, K1
Lazar, S1
Wurtzel, JGT1
Ma, P1
Goldfinger, LE1
Vukelic, M1
Laloo, A1
Kyttaris, VC1
Chen, R1
Chen, J3
Xun, J1
Hu, Z1
Huang, Q2
Steinhart, C1
Shen, Y1
Lu, H2
Mansuri, A1
Lokhande, K1
Kore, S1
Gaikwad, S1
Nawani, N1
Swamy, KV1
Junnarkar, M1
Pawar, S1
Shaheen, MY1
Basudan, AM1
Niazy, AA1
van den Beucken, JJJP1
Jansen, JA1
Alghamdi, HS1
Gao, Q2
Guo, X1
Cao, Y1
Jia, X1
Xu, S1
Lu, C2
Zhu, H2
Melku, M1
Abebe, G1
Teketel, A1
Asrie, F1
Yalew, A1
Biadgo, B1
Kassa, E1
Damtie, D1
Anlay, DZ1
Ahmed, MFE1
Ramadan, H1
Seinige, D1
Kehrenberg, C1
Abd El-Wahab, A1
Volkmann, N1
Kemper, N1
Schulz, J1
Hu, MY1
Wu, YN1
McEvoy, MP1
Wang, YF1
Cong, WL1
Liu, LP1
Li, XX1
Zhou, CL1
Chen, WM1
Wei, KL1
Tung, SY1
Shen, CH1
Chang, TS1
Yen, CW1
Hsieh, YY1
Chiu, WN1
Hu, JH1
Lu, SN1
Hung, CH1
Alakavuklar, MA1
Fuqua, C1
Luo, KL1
Underwood, RS1
Greenwald, I1
Elashiry, MM1
Elashiry, M1
Zeitoun, R1
Elsayed, R1
Tian, F5
Saber, SE1
Elashry, SH1
Tay, FR1
Cutler, CW1
O'Dowd, A1
Maciel, M1
Poole, ST1
Jobling, MG1
Rollenhagen, JE1
Woods, CM1
Sincock, SA1
McVeigh, AL1
Gregory, MJ1
Maves, RC1
Prouty, MG1
Holmes, RK1
Savarino, SJ1
Mor, MK1
Palevsky, PM1
Kaufman, JS1
Thiessen Philbrook, H1
Weisbord, SD1
Parikh, CR1
John, CM1
Phillips, NJ1
Jarvis, GA1
Zhu, Y1
Kilburn, S1
Kapoor, M1
Chaturvedi, S1
Shaw, KJ1
Chaturvedi, V1
Kong, X1
Zhang, T1
Xiao, H1
Feng, X1
Tu, H1
Feng, J1
Sabet, M1
Tarazi, Z1
Griffith, DC1
Nguyen, F1
Guan, P1
Guerrero, DT1
Kolla, V1
Naraparaju, K1
Perry, LM1
Soberman, D1
Pressly, BB1
Alferiev, IS1
Chorny, M1
Brodeur, GM1
Gao, X2
Cheng, YH1
Enten, GA1
DeSantis, AJ1
Gaponenko, V1
Majetschak, M1
Kim, DY1
Choi, MJ1
Ko, TK1
Lee, NH1
Kim, OH1
Cheon, HG1
Cai, H1
Yip, V1
Lee, MV1
Wong, S1
Saad, O1
Ma, S1
Ljumanovic, N1
Khojasteh, SC1
Kamath, AV1
Shen, BQ1
Cuypers, ML1
Chanteux, H1
Gillent, E1
Bonnaillie, P1
Saunders, K1
Beckers, C1
Delatour, C1
Dell'Aiera, S1
Ungell, AL1
Nicolaï, J1
Knapp, AK1
Chen, A1
Griffin-Nolan, RJ1
Baur, LE1
Carroll, CJW1
Gray, JE1
Hoffman, AM1
Li, X6
Post, AK1
Slette, IJ1
Collins, SL1
Luo, Y1
Smith, MD1
Temitayo, GI1
Olawande, B1
Emmanuel, YO1
Timothy, AT1
Kehinde, O1
Susan, LF1
Ezra, L1
Joseph, OO1
Lev, S1
Desmarini, D1
Liuwantara, D1
Sorrell, TC1
Hawthorne, WJ1
Djordjevic, JT1
Verso, MG1
Costantino, C1
Marrella, A1
Immordino, P1
Vitale, F1
Amodio, E1
Wang, YD1
Yao, WL1
Xin, ZM1
Han, TT1
Wang, ZG1
Chen, L1
Ba, D1
Wen, S1
Tian, Q1
Lv, W1
Cheng, G1
Li, N1
Yue, XY1
Chu, WJ1
Chen, Q1
Choi, ES1
Zhao, X3
Zhou, HD1
Sun, XF1
Sharma, S2
Chhoker, S1
Xie, C1
Ong, EWY1
Tan, ZK1
Evans, S1
Weinheimer, CJ1
Kovacs, A1
Williams, JW1
Randolph, GJ1
Jiang, W1
Barger, PM1
Mann, DL1
Liu, J2
Kong, L1
Yu, X1
Feng, B1
Liu, D1
Zhao, B1
Mendes, GC1
Yuan, P1
Ge, D1
Wang, WM1
Fontes, EPB1
Shan, L1
He, P1
Katoh, T1
Sengoku, T1
Hirata, K1
Ogata, K1
Suga, H1
Shun, C1
Yong-Yi, J1
Mei-Li, C1
Shi-Li, L1
Jian-Bo, Z1
Dan-Li, W1
Zhi-Min, G1
Ibrahim, AM1
Zakhary, SY1
Amin, SAW1
Ugurlu, M1
Fornari, VJ1
Hartmann, MSM1
Vanni, JR1
Rodriguez, R1
Langaro, MC1
Pelepenko, LE1
Zaia, AA1
Nakanjako, D1
Zalwango, F1
Wairagala, P1
Luboga, F1
Andia Biraro, I1
Bukirwa, VD1
Mboowa, MG1
Cose, S1
Seeley, J1
Elliott, A1
Zhao, G1
Sun, P1
Hao, S1
Qu, G1
Xing, Y1
Xu, X2
Maierhofer, M1
Rieger, V1
Mayr, T1
Zhang, Q2
Bigliardi, AP1
Fernandes, CLF1
Pinto, EA1
Dos Santos, M1
Garcia, EM1
Baisch, PRM1
Soares, MCF1
Muccillo-Baisch, AL1
da Silva Júnior, FMR1
Yu, W1
Ju, C1
Wang, K1
Zheng, Z1
Liu, H1
Gao, Y1
Martínez-Navarro, EM1
Cebrián-Tarancón, C1
Moratalla-López, N1
Lorenzo, C1
Alonso, GL1
Salinas, RM1
Bermúdez de Castro, JM1
Modesto-Mata, M1
Martín-Francés, L1
García-Campos, C1
Martínez de Pinillos, M1
Martinón-Torres, M1
Hasani, M1
Wu, F2
Warriner, K1
Kurz, M1
Gretzke, D1
Hörlein, R1
Turpault, S1
Atzrodt, J1
Derdau, V1
Yao, Y1
Ou, X1
Tian, B1
Jin, S1
Jiang, Z1
Zhou, Z1
Liu, M2
Jiang, GD1
Mou, LH1
Chen, JJ1
Li, ZY1
He, SG1
Reale, E1
Fustinoni, S1
Mercadante, R1
Polledri, E1
Hopf, NB1
Grant, PC1
Levy, K1
Lattimer, TA1
Depner, RM1
Kerr, CW1
Sato, J1
Merenda, MEZ1
Uemoto, AT1
Dos Santos, MP1
Barion, MRL1
Carciofi, AC1
de Paula Dorigam, JC1
Ribeiro, LB1
Vasconcellos, RS1
Waller, SB1
Peter, CM1
Hoffmann, JF1
Cleff, MB1
Faria de, RO1
Zani, JL1
Martins, BA1
Sande, D1
Solares, MD1
Takahashi, JA1
Yang, S2
Jia, Y1
Yin, C1
Zhao, R2
Ojha, M1
Wu, B1
Deepa, M1
Mo, J1
Au, DW1
Wan, MT1
Shi, J1
Zhang, G1
Winkler, C1
Kong, RY1
Seemann, F1
Bianco, M1
Calvano, CD1
Ventura, G1
Bianco, G1
Losito, I1
Cataldi, TRI1
Angiolella, L1
Staudt, A1
Duarte, PF1
Amaral, BPD1
Peixoto Andrade, BCO1
Simas, NK1
Correa Ramos Leal, I1
Sangenito, LS1
Santos, ALSD1
de Oliveira, D1
Junges, A1
Cansian, RL1
Paroul, N1
Siu, J1
Klingler, L1
Hung, CT1
Jeong, SH1
Smith, S1
Tingle, MD1
Wagner Mackenzie, B1
Biswas, K1
Douglas, RG1
Oza, AM1
Lorusso, D1
Aghajanian, C1
Oaknin, A1
Dean, A1
Colombo, N1
Weberpals, JI1
Clamp, AR1
Scambia, G1
Leary, A1
Holloway, RW1
Gancedo, MA1
Fong, PC1
Goh, JC1
O'Malley, DM1
Armstrong, DK1
Banerjee, S1
García-Donas, J1
Swisher, EM1
Cella, D1
Meunier, J1
Goble, S1
Cameron, T1
Maloney, L1
Mörk, AC1
Bedel, J1
Ledermann, JA1
Coleman, RL1
Vlek, SL1
Burm, R1
Govers, TM1
Vleugels, MPH1
Tuynman, JB1
Mijatovic, V1
Leicht, AS1
Connor, J1
Conduit, N1
Vaquera, A1
Gómez, MA1
McKay, JA1
Church, AL1
Rubin, N1
Emory, TH1
Hoven, NF1
Kuehn-Hajder, JE1
Nelson, MT1
Ramanna, S1
Auerbach, EJ1
Moeller, S1
Bolan, PJ1
Fox, NP1
Leonard, M1
Sjerps, MJ1
Chang, EF1
Hyun, S1
Saejio, A1
Shanmugam, S1
Sun, M1
Bai, Z1
Jaque-Fernandez, F1
Beaulant, A1
Berthier, C1
Monteiro, L1
Allard, B1
Casas, M1
Rieusset, J1
Jacquemond, V1
Góngora-García, OR1
Aca-Aca, G1
Baz-Rodríguez, SA1
Monte, A1
Maganaris, C1
Baltzopoulos, V1
Zamparo, P1
Wang, Z2
Hou, Y1
Cai, L1
Tu, YJ1
Tan, B1
Wu, ZH1
Yu, HJ1
Li, XQ1
Yang, AD1
Titze, IR1
Palaparthi, A1
Mau, T1
González, MA1
Goiri, F1
Barandika, JF1
García-Pérez, AL1
Jatt, LP1
Gandhi, MM1
Guo, R1
Sukhija-Cohen, A1
Bhattacharya, D1
Tseng, CH1
Chew, KW1
Onwumere, J1
Pia Tek, J1
Budnyak, T1
Budnyk, S1
Karim, Z1
Thersleff, T1
Kuśtrowski, P1
Mathew, AP1
Slabon, A1
Guo, M1
Zhao, T1
Xing, Z1
Qiu, Y1
Pan, K1
Li, Z2
Ghassemi Tabrizi, S1
Arbuznikov, AV1
Jiménez-Hoyos, CA1
Kaupp, M1
Lin, MH2
Bulman, DM1
Remucal, CK1
Chaplin, BP1
Laguerre, A1
George, LA1
Gall, ET1
Emerson, MS1
Wang, H3
Maginn, EJ1
Margulis, CJ1
Li, H2
Feng, W1
Kang, X2
Yan, S1
Chao, M1
Mo, S1
Sun, W1
Lu, Y1
Chen, C1
Stevens, DM1
Adiseshaiah, P1
Dasa, SSK1
Potter, TM1
Skoczen, SL1
Snapp, KS1
Cedrone, E1
Patel, N1
Busman-Sahay, K1
Rosen, EP1
Sykes, C1
Cottrell, M1
Dobrovolskaia, MA1
Estes, JD1
Kashuba, ADM1
Stern, ST1
Özütemiz, C1
Neil, EC1
Tanwar, M1
Rubin, NT1
Ozturk, K1
Cayci, Z1
Duscha, BD1
Kraus, WE1
Jones, WS1
Robbins, JL1
Piner, LW1
Huffman, KM1
Allen, JD1
Annex, BH1
Mehmood, T1
Ahmad, I1
Bibi, S1
Mustafa, B1
Ali, I1
Dahal, RH1
Chaudhary, DK1
Kim, DU1
Kim, J1
Yeter, HH1
Gonul, I1
Guz, G1
Helvaci, O1
Korucu, B1
Akcay, OF1
Derici, U1
Arinsoy, T1
Neffati, R1
Judeinstein, P1
Rault, J1
Chai, X1
Ren, T1
Yu, S1
Fu, Q2
Ye, J1
Ge, X1
Song, J1
Yang, H2
El-Baba, TJ1
Lutomski, CA1
Kantsadi, AL1
Malla, TR1
John, T1
Mikhailov, V1
Bolla, JR1
Schofield, CJ1
Zitzmann, N1
Vakonakis, I1
Robinson, CV1
Langham, MC1
Caporale, AS1
Wehrli, FW1
Parry, S1
Schwartz, N1
den Boer, RB1
Jones, KI1
Ash, S1
van Boxel, GI1
Gillies, RS1
O'Donnell, T1
Ruurda, JP1
Sgromo, B1
Silva, MA1
Maynard, ND1
Sivieri, EM1
Eichenwald, EC1
Rub, D1
Abbasi, S1
Krahnert, I1
Bolze, A1
Gibon, Y1
Fernie, AR1
Huang, L1
Wan, Y1
Dang, Z1
Yang, P1
Yang, Q1
Wu, S2
Lin, CC1
Hsu, CT1
Huang, SC1
Kortz, U1
Mougharbel, AS1
Chen, TY1
Hu, CW1
Lee, JF1
Wang, CC1
Liao, YF1
Li, LJ1
Li, L2
Peng, S1
Stimming, U1
Hebbar Kannur, K1
Yaqub, TB1
Pupier, C1
Héau, C1
Cavaleiro, A1
Yamamoto, S1
Ono, A1
Matsui, J1
Hoshino, N1
Akutagawa, T1
Miyashita, T1
Mitsuishi, M1
Patel, SM1
Smith, TG1
Morton, M1
Stiers, KM1
Seravalli, J1
Mayclin, SJ1
Edwards, TE1
Tanner, JJ1
Becker, DF1
Butcher, TW1
Yang, JL1
Hartwig, JF1
Yu, MF1
Xia, ZZ1
Yao, JC1
Li, DH1
Liu, T1
Cheng, GJ1
He, DL1
Li, XH1
Huurman, R1
Schinkel, AFL1
de Jong, PL1
van Slegtenhorst, MA1
Hirsch, A1
Michels, M1
Kataja, A1
Tarvasmäki, T1
Lassus, J1
Sionis, A1
Mebazaa, A1
Pulkki, K1
Banaszewski, M1
Carubelli, V1
Hongisto, M1
Jankowska, E1
Jurkko, R1
Jäntti, T1
Kasztura, M1
Parissis, J1
Sabell, T1
Silva-Cardoso, J1
Spinar, J1
Tolppanen, H1
Harjola, VP1
Carsetti, A1
Damiani, E1
Casarotta, E1
Scorcella, C1
Domizi, R1
Gasparri, F1
Gabbanelli, V1
Pantanetti, S1
Carozza, R1
Adrario, E1
Donati, A1
Almada, E1
Pariani, A1
Rivabella Maknis, T1
Hidalgo, F1
Vena, R1
Favre, C1
Larocca, MC1
Lu, ZY1
Jiang, WD1
Wu, P1
Kuang, SY1
Tang, L1
Yang, J1
Zhou, XQ1
Feng, L1
Leal, M1
Zampini, IC1
Mercado, MI1
Moreno, MA1
Simirgiotis, MJ1
Bórquez, J1
Ponessa, G1
Isla, MI1
Saliu, IO1
Amoo, ZA1
Khan, MF1
Olaleye, MT1
Rema, V1
Akinmoladun, AC1
Khan, AU1
Rahman, AU1
Yuan, Q1
Ahmad, A2
Khan, ZUH1
Mahnashi, MH1
Alyami, BA1
Alqahtani, YS1
Ullah, S1
Wirman, AP1
Gao, M2
Zhang, K1
Wang, M1
Xia, Z1
Gao, D1
Balkissou, AD1
Poka-Mayap, V1
Massongo, M1
Djenabou, A1
Endale-Mangamba, LM1
Olomo, EJ1
Boulleys-Nana, JR1
Diffo-Sonkoue, L1
Adidigue-Ndiome, R1
Alexandra, AJE1
Haman-Wabi, AB1
Adama, S1
Iddi-Faical, A1
Pefura-Yone, EW1
Zhao, Q1
Tong, W1
Ge, C1
Zhao, D1
Norbäck, D1
Li, B1
Zhao, Z1
Huang, C1
Qian, H1
Yang, X1
Sun, Y1
Sundell, J1
Deng, Q1
Kim, HJ1
Jeon, JW1
Hwang, SM1
Chu, KI1
Cha, YH1
Kwak, YD1
Choi, SD1
Aslam, M1
Kim, CG1
Zhou, J1
Yang, E1
Miao, L1
Guo, Y1
Yuan, R1
Tian, H1
Wang, XX1
Wang, F1
Mao, GH1
Wu, JC1
Li, M1
Han, R1
She, J1
Sheng, R1
Qin, ZH1
Yamashita, T2
Deguchi, K3
Omote, Y2
Kawai, H2
Ohta, Y1
Abe, K4
Okamura, K1
Tsubokawa, T1
Johshita, H1
Miyazaki, H1
Shiokawa, Y1
Dohare, P1
Hyzinski-García, MC1
Vipani, A1
Bowens, NH1
Nalwalk, JW1
Feustel, PJ1
Keller, RW1
Jourd'heuil, D1
Mongin, AA1
Yuan, Y1
Zha, H1
Rangarajan, P1
Ling, EA1
Aoyama, Y1
Ohta, S1
Sakaki, S1
Nishizawa, S1
Fujita, T1
Hua, K1
Sheng, X1
Li, TT1
Wang, LN1
Zhang, YH1
Huang, ZJ1
Ji, H1
Lan, Z1
Liang, Z1
Lei, M1
Zhao, C1
Hu, H1
Sun, Xo1
Liu, Q1
Tan, W1
Shen, LH2
Shen, HC1
Ye, M2
Liu, XF2
Ding, WS1
Sheng, YF1
Ding, XS2
Nonaka, Y1
Shimazawa, M1
Yoshimura, S1
Iwama, T1
Hara, H1
Okanishi, T1
Kondo, A1
Inoue, T1
Maegaki, Y1
Ohno, K1
Togari, H1
Yagi, K1
Kitazato, KT1
Uno, M1
Tada, Y1
Kinouchi, T1
Shimada, K1
Nagahiro, S1
Kamiya, T1
Inaba, T1
Shang, J2
Miyazaki, K2
Ohtsuka, A1
Katayama, Y1
Tanahashi, N1
Oka, F1
Fujisawa, H1
Nomura, S1
Kajiwara, K1
Kato, S1
Fujii, M1
Izuma, H1
Uozumi, K1
Gondo, T1
Suzuki, M1
Yamamoto, Y1
Yanagisawa, M1
Tak, NW1
Watanabe, K1
Takahashi, C1
Fujisawa, A1
Kashiba, M1
Tanaka, M1
Connell, BJ1
Saleh, TM1
Shi, WZ1
Zhang, YM1
Fang, SH1
Wei, EQ2
Liu, N2
Nishi, H1
Srinivasan, K1
Sharma, SS1
Zhang, P1
Wang, N1
Zheng, J1
Lei, S1
Kono, S1
Yunoki, T1
Deguchi, S1
Khan, MM1
Javed, H1
Raza, SS1
Ishrat, T1
Khan, MB1
Safhi, MM1
Islam, F1
Han, Q1
Huang, H1
Wu, EB1
Huang, HF1
Gu, XS1
Imamura, T1
Kiguchi, S1
Kobayashi, K1
Ichikawa, K1
Yamazaki, Y1
Kojima, M1
Yu, GL1
Zhang, SH1
Xu, HM1
Chu, LS1
Zhang, WP1
Mei, RH1
Zhao, MH1
Shichinohe, H1
Kuroda, S1
Yasuda, H1
Ishikawa, T1
Iwai, M1
Horiuchi, M1
Iwasaki, Y1
Inoue, A1
Fukumoto, SY1
Kumon, Y1
Watanabe, H1
Fumoto, N1
Oda, S1
Ohue, S1
Ohnishi, T1
Takizawa, S1
Izuhara, Y1
Kitao, Y1
Hori, O1
Ogawa, S1
Morita, Y1
Takagi, S1
van Ypersele de Strihou, C1
Miyata, T1
Nakamura, T1
Kume, T1
Katsuki, H1
Niidome, T1
Sugimoto, H1
Akaike, A1

Reviews

2 reviews available for edaravone and Infarction, Middle Cerebral Artery

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction].
    Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:1

    Topics: Antipyrine; Aortic Aneurysm, Thoracic; Aortic Dissection; Edaravone; Free Radical Scavengers; Humans

2009

Trials

1 trial available for edaravone and Infarction, Middle Cerebral Artery

ArticleYear
    Zeitschrift fur Gesundheitswissenschaften = Journal of public health, 2022, Volume: 30, Issue:2

    Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain;

2022

Other Studies

40 other studies available for edaravone and Infarction, Middle Cerebral Artery

ArticleYear
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
    Journal of medicinal chemistry, 2021, 04-08, Volume: 64, Issue:7

    Topics: Animals; Cell Line, Tumor; Cinnamates; Glucose; HEK293 Cells; Humans; Infarction, Middle Cerebral Ar

2021
Protective multi‑target effects of DL‑3‑n‑butylphthalide combined with 3‑methyl‑1‑phenyl‑2‑pyrazolin‑5‑one in mice with ischemic stroke.
    Molecular medicine reports, 2021, Volume: 24, Issue:6

    Topics: Animals; Apoptosis Regulatory Proteins; Benzofurans; Brain Ischemia; Disease Models, Animal; Drug Th

2021
Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats.
    Neurotoxicity research, 2022, Volume: 40, Issue:4

    Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Ischemi

2022
Edaravone Dexborneol Downregulates Neutrophil Extracellular Trap Expression and Ameliorates Blood-Brain Barrier Permeability in Acute Ischemic Stroke.
    Mediators of inflammation, 2022, Volume: 2022

    Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Deoxyribonuclease I; Edaravone; Extracellular Traps; H

2022
Edaravone Ameliorates Cerebral Ischemia-Reperfusion Injury by Downregulating Ferroptosis via the Nrf2/FPN Pathway in Rats.
    Biological & pharmaceutical bulletin, 2022, Volume: 45, Issue:9

    Topics: Animals; Brain Ischemia; Cation Transport Proteins; Edaravone; Ferroptosis; Glutathione; Infarction,

2022
Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke.
    International immunopharmacology, 2022, Volume: 113, Issue:Pt A

    Topics: Animals; Edaravone; Infarction, Middle Cerebral Artery; Inflammasomes; Ischemic Stroke; Mice; Microg

2022
A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats.
    European journal of pharmacology, 2023, Jul-15, Volume: 951

    Topics: Animals; Brain Ischemia; Edaravone; Infarction, Middle Cerebral Artery; Inflammation; Ischemic Strok

2023
Melatonin receptor agonist ramelteon attenuates mouse acute and chronic ischemic brain injury.
    Acta pharmacologica Sinica, 2020, Volume: 41, Issue:8

    Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Brain; Brain Injury, Chronic; Edaravone; Indenes;

2020
Edaravone-Loaded Macrophage-Derived Exosomes Enhance Neuroprotection in the Rat Permanent Middle Cerebral Artery Occlusion Model of Stroke.
    Molecular pharmaceutics, 2020, 09-08, Volume: 17, Issue:9

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Edaravone; Exosomes; Infarction, Middle Cerebral Ar

2020
Design, synthesis, and neuroprotective effects of novel hybrid compounds containing edaravone analogue and 3-n-butylphthalide ring-opened derivatives.
    Biochemical and biophysical research communications, 2021, 06-04, Volume: 556

    Topics: Animals; Apoptosis; Benzofurans; Brain Ischemia; Cell Line; Cell Line, Tumor; Drug Design; Edaravone

2021
NADPH is superior to NADH or edaravone in ameliorating metabolic disturbance and brain injury in ischemic stroke.
    Acta pharmacologica Sinica, 2022, Volume: 43, Issue:3

    Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Edaravone; Infarction, Middle Cer

2022
In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous bone marrow stromal cells (BMSCs) and edaravone.
    Neurological research, 2013, Volume: 35, Issue:10

    Topics: Animals; Antipyrine; Bone Marrow Cells; Bone Marrow Transplantation; Brain; Brain Ischemia; Disease

2013
Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia.
    Neurological research, 2014, Volume: 36, Issue:1

    Topics: Animals; Antipyrine; Blood Glucose; Brain; Cerebral Hemorrhage; Cerebral Infarction; Edaravone; Free

2014
The neuroprotective properties of the superoxide dismutase mimetic tempol correlate with its ability to reduce pathological glutamate release in a rodent model of stroke.
    Free radical biology & medicine, 2014, Volume: 77

    Topics: Alanine; Animals; Antipyrine; Astrocytes; Brain; Cells, Cultured; Cyclic N-Oxides; Drug Evaluation,

2014
Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
    BMC neuroscience, 2014, Nov-22, Volume: 15

    Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Apigenin; Brain; Brain Ischemia; Cell Count; Cell Lin

2014
[Case of spontaneous cervical internal carotid artery dissection with embolic stroke after a job-change].
    Journal of UOEH, 2014, Dec-01, Volume: 36, Issue:4

    Topics: Antipyrine; Arginine; Carotid Artery, Internal, Dissection; Diagnosis, Differential; Edaravone; Huma

2014
The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats.
    Acta pharmacologica Sinica, 2015, Volume: 36, Issue:8

    Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Benzofurans; Brain; Edaravone; Infarction, Middle Cere

2015
Discovery of 3-n-butyl-2,3-dihydro-1H-isoindol-1-one as a potential anti-ischemic stroke agent.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Animals; Antioxidants; Antipyrine; Behavior, Animal; Benzofurans; Biological Availability; Brain; Ca

2015
Neuroprotective Effects of Isosteviol Sodium Injection on Acute Focal Cerebral Ischemia in Rats.
    Oxidative medicine and cellular longevity, 2016, Volume: 2016

    Topics: Animals; Antipyrine; Brain; Dose-Response Relationship, Drug; Edaravone; Edema; Immunohistochemistry

2016
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model.
    Chinese medical journal, 2016, Jun-20, Volume: 129, Issue:12

    Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed

2016
Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice.
    Neuroscience letters, 2008, Aug-22, Volume: 441, Issue:2

    Topics: Animals; Antipyrine; Blood Pressure; Cell Death; Cerebral Infarction; Disease Models, Animal; Edarav

2008
Bilateral middle cerebral artery infarctions following mild varicella infection: a case report.
    Brain & development, 2009, Volume: 31, Issue:1

    Topics: Acyclovir; Antipyrine; Antiviral Agents; Chickenpox; Child, Preschool; DNA, Viral; Edaravone; Herpes

2009
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
    Stroke, 2009, Volume: 40, Issue:2

    Topics: Animals; Antipyrine; Blood Pressure; Blotting, Western; Brain Ischemia; Cells, Cultured; Cerebral He

2009
Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2009, Volume: 29, Issue:4

    Topics: Animals; Antipyrine; Basement Membrane; Brain Ischemia; Cerebral Hemorrhage; Edaravone; Free Radical

2009
Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model.
    Journal of neurotrauma, 2009, Volume: 26, Issue:9

    Topics: Animals; Antipyrine; Biomarkers; Brain Ischemia; Cerebrovascular Circulation; DNA Damage; Edaravone;

2009
Repeated edaravone treatment reduces oxidative cell damage in rat brain induced by middle cerebral artery occlusion.
    Redox report : communications in free radical research, 2009, Volume: 14, Issue:6

    Topics: Animals; Antioxidants; Antipyrine; Biomarkers; Brain; Brain Ischemia; Edaravone; Free Radical Scaven

2009
A novel rodent model of reperfusion injury following occlusion of the middle cerebral artery.
    Journal of neuroscience methods, 2010, Jun-30, Volume: 190, Issue:1

    Topics: Animals; Antipyrine; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship

2010
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:4

    Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chroni

2011
In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice.
    Brain research, 2011, Jun-23, Volume: 1397

    Topics: Animals; Annexin A5; Antipyrine; Apoptosis; Autophagy; Blood-Brain Barrier; Blotting, Western; Cereb

2011
Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress.
    Basic & clinical pharmacology & toxicology, 2012, Volume: 110, Issue:2

    Topics: Animals; Antipyrine; Apoptosis; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type

2012
Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury.
    Neuroscience, 2012, Jan-10, Volume: 201

    Topics: Analysis of Variance; Animals; Antipyrine; Bromodeoxyuridine; Cerebral Infarction; Cerebral Ventricl

2012
Modifying neurorepair and neuroregenerative factors with tPA and edaravone after transient middle cerebral artery occlusion in rat brain.
    Brain research, 2012, Feb-03, Volume: 1436

    Topics: Animals; Antipyrine; Brain; Chondroitin Sulfate Proteoglycans; Edaravone; Fibrinolytic Agents; Free

2012
Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat.
    Molecular and cellular biochemistry, 2012, Volume: 367, Issue:1-2

    Topics: Animals; Antipyrine; Apoptosis; Basal Ganglia; Caspase 3; Choline O-Acetyltransferase; Cholinergic N

2012
Protective effects of MCI-186 on transplantation of bone marrow stromal cells in rat ischemic stroke model.
    Neuroscience, 2012, Oct-25, Volume: 223

    Topics: Analysis of Variance; Animals; Animals, Newborn; Antipyrine; Brain; Brain Infarction; Brain-Derived

2012
Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
    Arzneimittel-Forschung, 2003, Volume: 53, Issue:10

    Topics: Animals; Antipyrine; Edaravone; Enzyme Inhibitors; Free Radical Scavengers; Infarction, Middle Cereb

2003
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
    Pharmacology, 2005, Volume: 73, Issue:1

    Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; C

2005
Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.
    Brain research, 2004, Dec-17, Volume: 1029, Issue:2

    Topics: Animals; Antipyrine; Brain Ischemia; DNA-Binding Proteins; Edaravone; Ethidium; Free Radical Scaveng

2004
[A case of common carotid artery dissection showing remission in short-term].
    No shinkei geka. Neurological surgery, 2005, Volume: 33, Issue:1

    Topics: Antipyrine; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Artery, Common; Drug Therap

2005
A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
    Brain research, 2007, Dec-05, Volume: 1183

    Topics: Animals; Antioxidants; Antipyrine; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cell Death; Do

2007
Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats.
    European journal of pharmacology, 2008, May-31, Volume: 586, Issue:1-3

    Topics: Animals; Antipyrine; Body Weight; Brain Ischemia; Cerebrovascular Circulation; Diterpenes; Dose-Resp

2008